Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A vaccines - Takeda

Next Previous
Drug Profile

Influenza A vaccines - Takeda

Alternative Names: BLB-750; Cell cultured influenza vaccine H5N1 TAKEDA 1mL; Cell cultured influenza vaccine H5N1 TAKEDA 5ml; Cell cultured influenza vaccine prototype TAKEDA 1mL; Cell cultured influenza vaccine prototype TAKEDA 5ml; Pandemic influenza vaccines - Takeda/National Resilience

Latest Information Update: 18 Jun 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype; Influenza A virus infections

Most Recent Events

  • 14 Dec 2017 Takeda initiates enrolment in a post-marketing phase IV trial for Influenza infections (In volunteers) in Japan (NCT03370289)
  • 07 Dec 2017 Takeda plans a post-marketing phase IV study of influenza A vaccine in healthy volunteers (JapicCTI-173797)
  • 07 Dec 2017 Launched for Influenza-A virus H5N1 subtype (Prevention) in Japan (Parenteral) before December 2017

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top